Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Teh Seng Pharmaceutical Mfg CoROCO:7860 +1.30%23 Return-on-Tangible-Equity is 12.90% as of Dec. 2025, which is 12% above its 10-year median of 11.52. GuruFocus rates ROCO:7860 with a GF Score™ of 23/100. The stock has 7 warning signs investors should review. Among 899 Drug Manufacturers companies, Teh Seng Pharmaceutical Mfg Co ranks better than 55.39% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Teh Seng Pharmaceutical Mfg Co's annualized net income for the quarter that ended in Dec. 2025 was NT$139.1 Mil. Teh Seng Pharmaceutical Mfg Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$1,078.7 Mil. Therefore, Teh Seng Pharmaceutical Mfg Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 12.90%.
The historical rank and industry rank for Teh Seng Pharmaceutical Mfg Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:7860'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 9.42 Med: 11.52 Max: 17.29
Current: 9.57
During the past 3 years, Teh Seng Pharmaceutical Mfg Co's highest Return-on-Tangible-Equity was 17.29%. The lowest was 9.42%. And the median was 11.52%.
ROCO:7860's Return-on-Tangible-Equity is ranked better than 55.39% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs ROCO:7860: 9.57
Teh Seng Pharmaceutical Mfg Co (ROCO:7860) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Teh Seng Pharmaceutical Mfg Co Return-on-Tangible-Equity Related Terms
Teh Seng Pharmaceutical Mfg Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teh Seng Pharmaceutical Mfg Co Return-on-Tangible-Equity Chart
Teh Seng Pharmaceutical Mfg Co Annual Data
Trend
Dec23
Dec24
Dec25
Return-on-Tangible-Equity
11.52
17.29
9.42
Teh Seng Pharmaceutical Mfg Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Return-on-Tangible-Equity
0.00
13.52
20.65
6.33
12.90
ROCO:7860 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teh Seng Pharmaceutical Mfg Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teh Seng Pharmaceutical Mfg Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teh Seng Pharmaceutical Mfg Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Teh Seng Pharmaceutical Mfg Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.90% mean?
Teh Seng Pharmaceutical Mfg Co (ROCO:7860) has a Return-on-Tangible-Equity of 12.90% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Teh Seng Pharmaceutical Mfg Co and its competitors. This is 12% above median its historical median of 11.52. Over the past decade, Teh Seng Pharmaceutical Mfg Co's Return-on-Tangible-Equity has ranged from 9.42 to 17.29. According to the industry distribution chart, Teh Seng Pharmaceutical Mfg Co ranks #401 out of 899 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Teh Seng Pharmaceutical Mfg Co's Return-on-Tangible-Equity too high?
Teh Seng Pharmaceutical Mfg Co's current Return-on-Tangible-Equity of 12.90% is 12% above median its 10-year median of 11.52. Over the past 10 years, this metric has ranged from a low of 9.42 to a high of 17.29. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Teh Seng Pharmaceutical Mfg Co's value of 12.90% is 63.3% above this industry median. Based on the distribution chart, Teh Seng Pharmaceutical Mfg Co ranks #401 out of 899 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Teh Seng Pharmaceutical Mfg Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Teh Seng Pharmaceutical Mfg Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teh Seng Pharmaceutical Mfg Co ranks #401 out of 899 companies for Return-on-Tangible-Equity. This puts Teh Seng Pharmaceutical Mfg Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Teh Seng Pharmaceutical Mfg Co's value of 12.90% is 63.3% above this benchmark. Historically, Teh Seng Pharmaceutical Mfg Co's own Return-on-Tangible-Equity has ranged from 9.42 to 17.29 over the past decade. While the company's 10-year median is 11.52 vs. the industry median of 7.90, Teh Seng Pharmaceutical Mfg Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teh Seng Pharmaceutical Mfg Co's current Return-on-Tangible-Equity of 12.90% is 63.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Teh Seng Pharmaceutical Mfg Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teh Seng Pharmaceutical Mfg Co's current Return-on-Tangible-Equity is 12.90%, which is 12% above median its own 10-year median of 11.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teh Seng Pharmaceutical Mfg Co stock overvalued right now?
Teh Seng Pharmaceutical Mfg Co (ROCO:7860) has a current Return-on-Tangible-Equity of 12.90%. The current Return-on-Tangible-Equity is 12.90%, which is 12% above median its 10-year median of 11.52 and 63.3% above the Drug Manufacturers industry median of 7.90. Teh Seng Pharmaceutical Mfg Co's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Teh Seng Pharmaceutical Mfg Co (ROCO:7860), the current Return-on-Tangible-Equity is 12.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Teh Seng Pharmaceutical Mfg Co Business Description
Teh Seng Pharmaceutical Mfg Co Ltd is engaged in the development and manufacturing of various pain relieving patches, cosmetic patches and biotechnology products. Its products include: Hydrogel Patches, Oil-Based Patches, Hot-Melt Patches, CMO & CRO for Transdermal Patch, Oral Film & Sublingual, Cosmetic Patches, Biotechnology Products and Daily Supplements.
23GF Score
Get the complete analysis for ROCO:7860
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7860 has been successfully added to your 
